Enqutinib is a tyrosine kinase inhibitor that can inhibit protein activity related to NTRK1/2/3, ROS1, and ALK gene fusion, thereby suppressing tumor cell proliferation.

1、 Indications

Enqutinib is a targeted inhibitor of neurotrophic tyrosine receptor kinase (NTRK) and ROS1, suitable for:

1. NTRK gene fusion positive solid tumor:

The treatment of NTRK gene fusion positive solid tumors in children and adult patients over one month old requires FDA approved testing confirmation.

Suitable for cases where metastatic or surgical resection may lead to serious complications, and there is progression or unsatisfactory alternative therapy after treatment.

2. ROS1 positive non-small cell lung cancer:

Used for adult patients with ROS1 positive metastatic non-small cell lung cancer.

2、 Usage and dosage

1. Dosage form:

Oral medication.

2. Recommended dosage:

Adults and children (body surface area ≥ 1.5m ²): 600mg once daily.

Children (body surface area<1.5m ²): Adjust the dosage according to body weight, once a day.

3. Attention:

It can be taken on an empty stomach or with meals.

If missed, if it is at least 12 hours before the next dose, it can be taken again; No need to take additional medication after vomiting.

3、 Side effects

1. Common adverse reactions:

Fatigue, constipation, taste disorders, edema, dizziness, diarrhea, nausea, abnormal sensation, difficulty breathing, etc.

2. Serious risk:

Congestive heart failure: cardiac function needs to be monitored, and medication should be temporarily or permanently discontinued when symptoms appear.

Central nervous system effects: may cause cognitive impairment, emotional changes, or dizziness.

Hepatotoxicity: Regular monitoring of liver function is necessary, and medication should be suspended when ALT/AST levels increase by ≥ 3 times.

Fracture risk: Long term use may increase the probability of fractures.

4、 Medication precautions

1. Contraindications: It is contraindicated for individuals who are allergic to erlotinib or excipients.

2. Monitoring requirements:

Regularly check heart function, liver function, and electrolytes before and during treatment.

Child patients need to monitor their growth and development.

3. Drug interactions:

Avoid using potent CYP3A4 inhibitors (such as ketoconazole) or inducers (such as rifampicin) in combination.

4. Special populations:

Pregnant women are prohibited from using it (which may cause harm to the fetus), and medication or breastfeeding should be stopped during lactation.

Elderly patients do not need to adjust their dosage, but close monitoring of adverse reactions is necessary.

5、 Storage method

Store in the dark at 20 ° C-25 ° C (allowing short-term fluctuations of 15 ° C-30 ° C).

Oral granules should be kept dry to avoid moisture.

entrectinibinformation